Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1065890 in Adult Participants With Tardive Dyskinesia

NCT07365462 is registered in ClinicalTrials.gov with Neurocrine Biosciences as lead sponsor.

NCT NCT07365462
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07365462 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1065890 in Adult Participants With Tardive Dyskinesia
Lead sponsor
Neurocrine Biosciences
Phase
Phase 2
Overall status
Recruiting
Start date
February 6, 2026
Completion date
March 31, 2027
Enrollment
100 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

tardive dyskinesia